Inovio Pharmaceuticals Company Profile (NASDAQ:INO)

About Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals logoInovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:INO
  • CUSIP: N/A
  • Web: www.inovio.com
Capitalization:
  • Market Cap: $529.11 million
  • Outstanding Shares: 74,627,000
Average Prices:
  • 50 Day Moving Avg: $6.48
  • 200 Day Moving Avg: $6.77
  • 52 Week Range: $5.83 - $11.61
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.21
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $37.63 million
  • Price / Sales: 14.06
  • Book Value: $1.42 per share
  • Price / Book: 4.99
Profitability:
  • EBIDTA: ($80,300,000.00)
  • Net Margins: -199.99%
  • Return on Equity: -39.93%
  • Return on Assets: -31.81%
Debt:
  • Current Ratio: 3.39%
  • Quick Ratio: 3.39%
Misc:
  • Average Volume: 776,167 shs.
  • Beta: 2.84
  • Short Ratio: 14.95
 

Frequently Asked Questions for Inovio Pharmaceuticals (NASDAQ:INO)

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Inovio Pharmaceuticals's stock reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals Inc (NASDAQ:INO) issued its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.31) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.31). The company earned $10.40 million during the quarter, compared to analysts' expectations of $5.83 million. Inovio Pharmaceuticals had a negative net margin of 199.99% and a negative return on equity of 39.93%. Inovio Pharmaceuticals's revenue was up 28.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.11) EPS. View Inovio Pharmaceuticals' Earnings History.

Where is Inovio Pharmaceuticals' stock going? Where will Inovio Pharmaceuticals' stock price be in 2017?

10 brokers have issued twelve-month price objectives for Inovio Pharmaceuticals' stock. Their forecasts range from $9.00 to $40.00. On average, they expect Inovio Pharmaceuticals' stock price to reach $20.60 in the next year. View Analyst Ratings for Inovio Pharmaceuticals.

What are analysts saying about Inovio Pharmaceuticals stock?

Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Inovio reported narrower than expected loss in first quarter of 2017, with revenue beating estimates. Inovio is a development-stage biopharmaceutical company is focused on the development of treatments targeting various forms of cancer and infectious diseases. We are pleased with the company’s collaborations with other firms for pipeline development. Shares of Inovio have outperformed the Medical-Biomedical/Genetics industry so far this year. However, Inovio suffered a setback with the FDA placing clinical hold on the proposed phase III program on its lead pipeline candidate, VGX-3100 in Oct 2016. Though in Apr 2017, Inovio submitted a complete response to the FDA for the initiation of the study, FDA decision is still pending. Moreover, Inovio’s over-dependence on government grants and contracts for the development of its candidates is also concerning." (5/15/2017)
  • 2. Maxim Group analysts commented, "Inovio reported 1Q17 with $10M in revenue (collaborations, partnerships) and operating expenses of $32M, for a net loss of $23M. The company ended the period with $90M, or ~three quarters of cash at the current burn rate." (5/11/2017)

Who are some of Inovio Pharmaceuticals' key competitors?

Who owns Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.18%), State Street Corp (3.37%), Morgan Stanley (0.89%), Geode Capital Management LLC (0.76%), Bank of New York Mellon Corp (0.46%) and Schwab Charles Investment Management Inc. (0.41%). Company insiders that own Inovio Pharmaceuticals stock include Jong Joseph Kim, Morton Collins, Niranjan Sardesai and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.

Who sold Inovio Pharmaceuticals stock? Who is selling Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, UBS Group AG, State Street Corp, Goldman Sachs Group Inc., Alliancebernstein L.P., TIAA CREF Investment Management LLC, ProShare Advisors LLC and Bellevue Group AG. Company insiders that have sold Inovio Pharmaceuticals stock in the last year include Jong Joseph Kim and Niranjan Sardesai. View Insider Buying and Selling for Inovio Pharmaceuticals.

Who bought Inovio Pharmaceuticals stock? Who is buying Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Credit Suisse AG, Geode Capital Management LLC, Wells Fargo & Company MN, Vident Investment Advisory LLC, Schwab Charles Investment Management Inc., Bank of New York Mellon Corp and Metropolitan Life Insurance Co. NY. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Morton Collins, Niranjan Sardesai and Simon X Benito. View Insider Buying and Selling for Inovio Pharmaceuticals.

How do I buy Inovio Pharmaceuticals stock?

Shares of Inovio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Inovio Pharmaceuticals stock cost?

One share of Inovio Pharmaceuticals stock can currently be purchased for approximately $7.09.

Analyst Ratings

Consensus Ratings for Inovio Pharmaceuticals (NASDAQ:INO) (?)
Ratings Breakdown: 3 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.70)
Consensus Price Target: $20.60 (190.55% upside)

Analysts' Ratings History for Inovio Pharmaceuticals (NASDAQ:INO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/17/2017AegisReiterated RatingBuy$11.00LowView Rating Details
5/11/2017HC WainwrightSet Price TargetBuy$13.00LowView Rating Details
5/11/2017Maxim GroupReiterated RatingBuyHighView Rating Details
5/1/2017NomuraReiterated RatingBuy$40.00LowView Rating Details
5/1/2017Jefferies Group LLCReiterated RatingNeutral$38.00LowView Rating Details
5/1/2017BNP ParibasReiterated RatingNeutral$39.00LowView Rating Details
4/25/2017Stifel NicolausReiterated RatingBuy$11.00HighView Rating Details
3/16/2017Piper Jaffray CompaniesDowngradeOverweight -> Neutral$13.00 -> $9.00HighView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$18.00N/AView Rating Details
6/21/2016Rodman & RenshawReiterated RatingBuy$17.00N/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Inovio Pharmaceuticals (NASDAQ:INO)
Earnings by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Earnings History by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.31)($0.31)$5.83 million$10.40 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.29)($0.35)$5.21 million$8.50 millionViewN/AView Earnings Details
11/9/2016Q316($0.26)($0.28)$5.16 million$12.54 millionViewListenView Earnings Details
8/8/2016Q2($0.21)($0.26)$4.95 million$6.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.14)($0.11)$4.75 million$8.10 millionViewN/AView Earnings Details
3/14/2016Q4($0.20)($0.25)$6.96 million$5.94 millionViewListenView Earnings Details
11/9/2015Q3$0.04$0.07$1.84 million$24.18 millionViewN/AView Earnings Details
8/10/2015Q215($0.13)($0.10)$5.52 million$5.30 millionViewListenView Earnings Details
5/11/2015Q1($0.11)($0.18)$7.04 million$5.20 millionViewListenView Earnings Details
3/16/2015Q414($0.10)($0.12)$5.24 million$2.50 millionViewN/AView Earnings Details
11/10/2014Q314($0.11)($0.12)$5.60 million$1.80 millionViewN/AView Earnings Details
8/11/2014Q214($0.17)($0.19)$1.80 million$3.80 millionViewN/AView Earnings Details
5/12/2014Q114($0.04)($0.05)$1.41 million$2.40 millionViewN/AView Earnings Details
3/17/2014Q413($0.03)($0.04)$1.36 million$1.70 millionViewN/AView Earnings Details
11/11/2013Q3($0.02)($0.16)$2.99 million$9.50 millionViewListenView Earnings Details
11/7/2012Q312($0.05)($0.05)$2.07 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Inovio Pharmaceuticals (NASDAQ:INO)
Current Year EPS Consensus Estimate: $-1.08 EPS
Next Year EPS Consensus Estimate: $-1.36 EPS

Dividends

Dividend History for Inovio Pharmaceuticals (NASDAQ:INO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Inovio Pharmaceuticals (NASDAQ:INO)
Insider Ownership Percentage: 9.90%
Institutional Ownership Percentage: 28.72%
Insider Trades by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Insider Trades by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/31/2017Jong Joseph KimCEOSell147,180$6.54$962,557.20View SEC Filing  
3/27/2017Morton CollinsDirectorBuy21,300$6.25$133,125.00View SEC Filing  
8/29/2016Niranjan SardesaiCOOSell21,800$9.30$202,740.00View SEC Filing  
6/28/2016Morton CollinsDirectorBuy10,000$9.13$91,300.00View SEC Filing  
5/18/2016Simon X BenitoDirectorSell6,250$10.37$64,812.50View SEC Filing  
4/15/2016Morton CollinsDirectorBuy68,400$9.52$651,168.00View SEC Filing  
9/30/2015Niranjan SardesaiCOOBuy4,000$5.50$22,000.00View SEC Filing  
8/14/2015Simon X BenitoDirectorBuy6,000$7.21$43,260.00View SEC Filing  
4/13/2015Angel CabreraDirectorBuy8,000$9.53$76,240.00View SEC Filing  
10/9/2014Peter KiesCFOBuy3,960$10.10$39,996.00View SEC Filing  
8/21/2014Morton CollinsDirectorBuy8,000$10.01$80,080.00View SEC Filing  
8/20/2014Morton CollinsDirectorBuy40,600$9.74$395,444.00View SEC Filing  
8/12/2014Jong Joseph KimCEOBuy250,000$9.06$2,265,000.00View SEC Filing  
8/12/2014Niranjan SardesaiCOOBuy2,550$8.70$22,185.00View SEC Filing  
4/15/2014Jong Joseph KimCEOBuy25,000$2.25$56,250.00View SEC Filing  
11/13/2013Morton CollinsDirectorBuy254,500$1.82$463,190.00View SEC Filing  
4/16/2013Mark BagarazziInsiderBuy60,000$0.56$33,600.00View SEC Filing  
4/2/2013Jong Joseph KimCEOBuy90,000$0.50$45,000.00View SEC Filing  
3/22/2013Angel CabreraDirectorBuy40,000$0.54$21,600.00View SEC Filing  
3/20/2013Jong Joseph KimCEOBuy60,000$0.53$31,800.00View SEC Filing  
3/20/2013Niranjan SardesaiCOOBuy25,000$0.53$13,250.00View SEC Filing  
1/15/2013Morton CollinsDirectorBuy100,000$0.67$67,000.00View SEC Filing  
11/14/2012Austin W & Greenhouse Da MarxeMajor ShareholderSell622,550$0.53$329,951.50View SEC Filing  
8/15/2012Angel CabreraDirectorBuy75,000$0.59$44,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Inovio Pharmaceuticals (NASDAQ:INO)
Latest Headlines for Inovio Pharmaceuticals (NASDAQ:INO)
Source:
DateHeadline
americanbankingnews.com logoInovio Pharmaceuticals Inc (INO) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 19 at 8:58 PM
seekingalpha.com logoWhy Inovio Surged 13% This Week - Seeking Alpha
seekingalpha.com - May 19 at 10:29 AM
americanbankingnews.com logoInovio Pharmaceuticals' (INO) "Buy" Rating Reiterated at Aegis
www.americanbankingnews.com - May 17 at 5:56 PM
americanbankingnews.com logoInovio Pharmaceuticals Inc (INO) Expected to Announce Quarterly Sales of $18.75 Million
www.americanbankingnews.com - May 17 at 10:52 AM
finance.yahoo.com logoETFs with exposure to Inovio Pharmaceuticals, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 5:27 PM
americanbankingnews.com logoZacks Investment Research Upgrades Inovio Pharmaceuticals Inc (INO) to "Hold"
www.americanbankingnews.com - May 15 at 12:24 PM
finance.yahoo.com logoInovio (INO) Q1 Loss Narrower Than Expected, Revenues Beat - Yahoo Finance
finance.yahoo.com - May 14 at 8:13 AM
americanbankingnews.com logoInovio Pharmaceuticals Inc (INO) Receives Buy Rating from Maxim Group
www.americanbankingnews.com - May 13 at 11:56 PM
americanbankingnews.com logoInovio Pharmaceuticals Inc (INO) Given a $13.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - May 13 at 6:58 PM
finance.yahoo.com logoInovio Pharmaceuticals, Inc. :INO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - May 12 at 6:37 PM
nasdaq.com logoInovio Pharmaceuticals Reports 2017 First Quarter Financial Results - Nasdaq
www.nasdaq.com - May 11 at 11:31 PM
americanbankingnews.com logoInovio Pharmaceuticals Inc (INO) Announces Quarterly Earnings Results, Meets Estimates
www.americanbankingnews.com - May 11 at 10:52 PM
finance.yahoo.com logoInovio (INO) Q1 Loss Narrower Than Expected, Revenues Beat
finance.yahoo.com - May 11 at 6:30 PM
rttnews.com logoEARNINGS SUMMARY: Details of Inovio Pharmaceuticals Inc. Q1 Earnings Report
www.rttnews.com - May 10 at 11:21 PM
seekingalpha.com logoInovio Pharmaceuticals' (INO) CEO J. Joseph Kim on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 11:21 PM
globenewswire.com logoInovio Pharmaceuticals Reports 2017 First Quarter Financial Results - GlobeNewswire (press release)
globenewswire.com - May 10 at 6:20 PM
finance.yahoo.com logoInovio Pharmaceuticals Reports 2017 First Quarter Financial Results
finance.yahoo.com - May 10 at 6:20 PM
finance.yahoo.com logoInovio reports 1Q loss
finance.yahoo.com - May 10 at 6:20 PM
globenewswire.com logoInovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer - GlobeNewswire (press release)
globenewswire.com - May 10 at 1:19 PM
finance.yahoo.com logoInovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer
finance.yahoo.com - May 10 at 1:19 PM
finance.yahoo.com logoInovio Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : INO-US : May 9, 2017
finance.yahoo.com - May 9 at 12:24 PM
finance.yahoo.com logoInovio Pharmaceuticals to Participate in Bank of America Merrill Lynch 2017 Healthcare Conference - Yahoo Finance
finance.yahoo.com - May 4 at 8:16 AM
finance.yahoo.com logoWhat's in the Cards for Inovio (INO) This Earnings Season? - Yahoo Finance
finance.yahoo.com - May 4 at 8:16 AM
globenewswire.com logoInovio Pharmaceuticals to Participate in Bank of America Merrill Lynch 2017 Healthcare Conference
globenewswire.com - May 2 at 4:22 PM
nasdaq.com logoInovio Pharmaceuticals to Participate in Bank of America Merrill Lynch 2017 Healthcare Conference - Nasdaq
www.nasdaq.com - May 2 at 10:27 AM
finance.yahoo.com logoInovio Pharmaceuticals to Participate in Bank of America Merrill Lynch 2017 Healthcare Conference
finance.yahoo.com - May 2 at 10:27 AM
americanbankingnews.com logoInovio Pharmaceuticals Inc (INO) Receives "Neutral" Rating from BNP Paribas
www.americanbankingnews.com - May 1 at 6:40 PM
americanbankingnews.com logoInovio Pharmaceuticals Inc (INO) Earns "Neutral" Rating from Jefferies Group LLC
www.americanbankingnews.com - May 1 at 6:40 PM
americanbankingnews.com logoNomura Reaffirms Buy Rating for Inovio Pharmaceuticals Inc (INO)
www.americanbankingnews.com - May 1 at 6:40 PM
americanbankingnews.com logoPositive News Coverage Likely to Impact Inovio Pharmaceuticals (INO) Stock Price
www.americanbankingnews.com - April 28 at 12:56 AM
finance.yahoo.com logoInovio Pharmaceuticals to Report First Quarter 2017 Financial Results May 10, 2017
finance.yahoo.com - April 26 at 7:23 PM
finance.yahoo.com logoInovio Pharmaceuticals, Inc. – Value Analysis (NASDAQ:INO) : April 26, 2017
finance.yahoo.com - April 26 at 7:23 PM
streetinsider.com logoInovio Pharma (INO) Commences Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers
www.streetinsider.com - April 25 at 10:41 AM
reuters.com logoBRIEF-Inovio initiates Phase 2 efficacy trial with VGX-3100 for HPV-related vulvar pre-cancers
www.reuters.com - April 25 at 10:41 AM
finance.yahoo.com logoWhy Is Inovio (INO) Down 2% Since the Last Earnings Report?
finance.yahoo.com - April 25 at 10:41 AM
finance.yahoo.com logoInovio Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : INO-US : April 25, 2017
finance.yahoo.com - April 25 at 10:41 AM
americanbankingnews.com logoInovio Pharmaceuticals Inc (INO) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 24 at 9:42 PM
americanbankingnews.com logoInovio Pharmaceuticals (INO) Given Daily Media Sentiment Score of 0.02
www.americanbankingnews.com - April 24 at 6:36 PM
globenewswire.com logoInovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers - GlobeNewswire (press release)
globenewswire.com - April 24 at 5:36 PM
finance.yahoo.com logoInovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers
finance.yahoo.com - April 24 at 9:32 AM
americanbankingnews.com logoSomewhat Positive Media Coverage Likely to Impact Inovio Pharmaceuticals (INO) Share Price
www.americanbankingnews.com - April 21 at 11:30 PM
fool.com logoInovio Pharmaceuticals Stock History: From A to Zika - Motley Fool
www.fool.com - April 19 at 5:47 PM
americanbankingnews.com logoSomewhat Positive Press Coverage Very Likely to Affect Inovio Pharmaceuticals (INO) Stock Price
www.americanbankingnews.com - April 18 at 6:03 PM
businesswire.com logoInovio Pharmaceuticals to Implement Pilgrim Quality Solutions in the Cloud - Business Wire (press release)
www.businesswire.com - April 18 at 5:26 PM
finance.yahoo.com logoInovio Pharmaceuticals Stock History: From A to Zika
finance.yahoo.com - April 18 at 5:26 PM
americanbankingnews.com logoInovio Pharmaceuticals Inc (INO) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 17 at 1:50 PM
finance.yahoo.com logoInovio's Ebola Vaccine Positive in Expanded Phase I Study
finance.yahoo.com - April 12 at 6:13 PM
finance.yahoo.com logoInovio's Ebola Vaccine Positive in Expanded Phase I Study
finance.yahoo.com - April 12 at 6:13 PM
bizjournals.com logoResearch Reports Initiation on Biotech Stocks -- Tesaro, Alnylam Pharma, Corbus Pharma, and Inovio Pharma
www.bizjournals.com - April 12 at 9:04 AM
fool.com logoThis Survey's Bad News Could Be Good News for Inovio Pharmaceuticals, Inc.
www.fool.com - April 12 at 9:04 AM

Social

Inovio Pharmaceuticals (INO) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff